Provider Dashboard

Total Patients

1,234

Upcoming Appointments

15

Pending Reports

7

Recent Consultations

28

Notifications

View All Inbox
Message from Sarah Adams

Question about increased bruising with ibrutinib

10 min ago
New CBC ResultsCritical

James Wilson - Critical: Platelets 22 × 10^9/L

32 min ago
PET/CT Results Available

Emily Clark - Follow-up for lymphoma treatment

2 hours ago
Message from Maria GarciaCritical

Experiencing fever after chemotherapy

6 hours ago
Earlier Today
Message from Robert Johnson

Requesting appointment change for next week

1 hour ago
New Bone Marrow Biopsy Report

David Patel - Post-treatment assessment

3 hours ago
Apheresis Procedure Note

Lisa Martinez - Stem cell collection completed

5 hours ago
New Coagulation PanelCritical

Thomas Wright - INR 3.6, PT 34s

8 hours ago
MRI Results Available

Samantha Lee - Extramedullary disease assessment

Yesterday

Relevant Research

AI-recommended for your patients

Long-term outcomes of ibrutinib in patients with chronic lymphocytic leukemia: 8-year follow-up of phase 3 RESONATE-2 study

Journal of Clinical Oncology•February 2025•DOI: 10.1200/JCO.24.00831
3 CLL patients in your panel

Improved outcomes with early intervention for venetoclax-associated neutropenia in AML

Blood•January 2025•DOI: 10.1182/blood.2024019433
4 AML patients in your panel

Risk-adapted prophylaxis for pneumocystis pneumonia in hematologic malignancies

Leukemia•February 2025•DOI: 10.1038/s41375-024-01567-8
Applies to multiple patients

Real-world experience with polatuzumab-based therapy for relapsed/refractory DLBCL

Hematological Oncology•January 2025•DOI: 10.1002/hon.3175
1 DLBCL patient (Lee)

Iron deficiency management in cancer-related anemia: intravenous versus oral supplementation

Supportive Care in Cancer•February 2025•DOI: 10.1007/s00520-024-07889-8
Multiple patients with therapy-induced anemia

Early results of chimeric antigen receptor T-cell therapy in elderly patients with high-risk hematological malignancies

Nature Medicine•January 2025•DOI: 10.1038/s41591-024-02700-9
2 potential CAR-T candidates in your panel